Eli Lilly Stock 8-Day Losing Spree: Stock Falls -10%
Eli Lilly (LLY) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -10% return. The company has lost about $77 Bil in value over the last 8 days, with its current market capitalization at about $685 Bil. The stock remains 30.2% above its value at the end of 2024. This compares with year-to-date returns of 16.4% for the S&P 500.
Eli Lilly’s recent streak reflected profit-taking after its $1 trillion valuation and a ~50x earnings multiple, as investors weighed intensified GLP-1 competition and pricing pressures from new government deals and China’s Mounjaro inclusion, despite robust Q3 revenue growth.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Our take: There is not much to fear in LLY stock given its overall Very Strong operating performance and financial condition. Hence, despite its Very High valuation, the stock appears Attractive but Volatile (see Buy or Sell LLY).
For quick background, LLY provides innovative pharmaceuticals globally, including treatments for cancer, rheumatoid arthritis, and autoimmune diseases such as psoriasis and ankylosing spondylitis.
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
Comparing LLY Stock Returns With The S&P 500
The following table summarizes the return for LLY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LLY | S&P 500 |
|---|---|---|
| 1D | -1.3% | -0.3% |
| 8D (Current Streak) | -10.1% | 1.2% |
| 1M (21D) | 6.6% | 1.9% |
| 3M (63D) | 33.1% | 5.1% |
| YTD 2025 | 30.2% | 16.4% |
| 2024 | 33.3% | 23.3% |
| 2023 | 60.9% | 24.2% |
| 2022 | 34.3% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 53 S&P constituents with 3 days or more of consecutive gains and 104 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 8 | 52 |
| 4D | 22 | 14 |
| 5D | 20 | 6 |
| 6D | 0 | 22 |
| 7D or more | 3 | 10 |
| Total >=3 D | 53 | 104 |
Key Financials for Eli Lilly (LLY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $34.1 Bil | $45.0 Bil |
| Operating Income | $10.8 Bil | $17.5 Bil |
| Net Income | $5.2 Bil | $10.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $12.7 Bil | $15.6 Bil |
| Operating Income | $5.4 Bil | $7.1 Bil |
| Net Income | $2.8 Bil | $5.7 Bil |
The losing streak LLY stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.